Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: incidence and consequences
- PMID: 23331474
- DOI: 10.1111/ajt.12009
Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: incidence and consequences
Abstract
The natural history and clinical significance of posttransplant Epstein-Barr virus (EBV) infection remain largely unknown. The aims of this study are to describe the incidence, risk factors and consequences of EBV infection after kidney transplantation. A total of 383 consecutive patients having received a kidney transplant between January 2002 and December 2010 were included. EBV polymerase chain reaction (PCR) was performed every 2 weeks for 3 months, and every 4 weeks for the next 9 months. A total of 155 of the 383 patients (40%) had at least one positive viremia during the first year posttransplant. The median time to viremia was day 31 posttransplant (14-329). A total of 73 (47%) had EBV viremia > 10(3) log and 23 (15%) had positive viremia for more than 6 months. EBV D+/R- patients (12/18 (67%) versus 143/365 (39%), p = 0.02) and those having received antithymocyte globulins (ATG) (54% vs. 35%; p<0.001) were more likely to develop EBV infection. EBV infection (hazard ratio [HR], 3.03; 95% confidence interval [CI], 1.72-8.29; p = 0.01) was associated with the occurrence of opportunistic infections. A positive EBV PCR during the first 6 months posttransplant was associated with graft loss (HR, 3.04; 95% CI, 1.36-6.79; p = 0.014). EBV reactivation is frequent after transplantation and reflects overimmunosuppression. Prospective studies should examine the association between EBV and graft loss.
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
Comment in
-
The role of CMV and EBV in renal allograft loss.Am J Transplant. 2013 Aug;13(8):2229. doi: 10.1111/ajt.12334. Epub 2013 Jul 10. Am J Transplant. 2013. PMID: 23841914 No abstract available.
-
The role of CMV and EBV renal allograft loss--reply.Am J Transplant. 2013 Aug;13(8):2230. doi: 10.1111/ajt.12339. Am J Transplant. 2013. PMID: 23890288 No abstract available.
Similar articles
-
Late Persistent Positive EBV Viral Load and Risk of Solid Cancer in Kidney Transplant Patients.Transplantation. 2017 Jun;101(6):1473-1478. doi: 10.1097/TP.0000000000001280. Transplantation. 2017. PMID: 27367471
-
The simultaneous presence of active BK, Epstein Barr, and human cytomegalovirus infection and their correlation by host factors in patients suspected of kidney transplant rejection.BMC Infect Dis. 2024 Sep 9;24(1):937. doi: 10.1186/s12879-024-09821-z. BMC Infect Dis. 2024. PMID: 39251898 Free PMC article.
-
Epstein-Barr virus and renal transplantation.Transplant Rev (Orlando). 2017 Jan;31(1):55-60. doi: 10.1016/j.trre.2016.12.001. Epub 2016 Dec 29. Transplant Rev (Orlando). 2017. PMID: 28089555 Review.
-
Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.Pediatr Nephrol. 2020 Mar;35(3):427-439. doi: 10.1007/s00467-019-04401-9. Epub 2019 Dec 4. Pediatr Nephrol. 2020. PMID: 31802220 Free PMC article.
-
Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature.Transpl Infect Dis. 2019 Feb;21(1):e13010. doi: 10.1111/tid.13010. Epub 2018 Oct 25. Transpl Infect Dis. 2019. PMID: 30298678 Review.
Cited by
-
Single-Center Outcomes of Epstein-Barr Virus DNAemia in Adult Solid Organ Transplant Recipients.J Transplant. 2024 Jan 18;2024:5598324. doi: 10.1155/2024/5598324. eCollection 2024. J Transplant. 2024. PMID: 38283325 Free PMC article.
-
Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.Transpl Infect Dis. 2020 Dec;22(6):e13396. doi: 10.1111/tid.13396. Epub 2020 Jul 27. Transpl Infect Dis. 2020. PMID: 32603496 Free PMC article. Review.
-
Viral surveillance and subclinical viral infection in pediatric kidney transplantation.Pediatr Nephrol. 2015 May;30(5):741-8. doi: 10.1007/s00467-014-2866-8. Epub 2014 Aug 16. Pediatr Nephrol. 2015. PMID: 25125226 Free PMC article. Review.
-
Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study.Transplant Direct. 2017 Jun 26;3(7):e182. doi: 10.1097/TXD.0000000000000703. eCollection 2017 Jul. Transplant Direct. 2017. PMID: 28706985 Free PMC article.
-
Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.Front Immunol. 2020 Jun 17;11:1231. doi: 10.3389/fimmu.2020.01231. eCollection 2020. Front Immunol. 2020. PMID: 32625211 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical